Lorcaserin

I-CMOAPI inoluhlu olupheleleyo lwezixhobo eziluhlaza ze-lorcaserin, kwaye inolawulo olupheleleyo lwenkqubo.Also yadlula i-GMP kunye nesiqinisekiso se-DMF.

Ibonisa i-1-3 yeziphumo ezingama-6

1 2

Kuphi ukuthenga iLorcaserin kunye nabaPhakathi bayo?

Unokwenza i-lorcaserin ithenge kwiivenkile ezikwi-intanethi. Umgubo ufumaneka ngesixa esikhulu kubaphandi nakwabahlalutyi. Xa injongo yakho kukulahla iipawundi ezongezelelekileyo ngenxa yokutyeba kakhulu, unokujonga i-lorcaserin ethengiswa kwi-Intanethi. Nangona kunjalo, unokufuna amayeza ngenxa yesikhokelo esingqongqo yi-FDA.
Ukuba ujonga i-lorcaserin okanye i-intermediates yayo, kuya kufuneka ungene kunye ne-CMOAPI ngonikezelo olusebenzayo lweemveliso ezihlambulukileyo. Amakhompawundi ethu afumene isiqinisekiso somgangatho.


I-Lorcaserin-Infographic-01 I-Lorcaserin-Infographic-02 I-Lorcaserin-Infographic-03

ILorcaserin FAQ

Ndiyithatha njani i-belviq yeziphumo ezilungileyo?

Ginya ithebhulethi ekhululwe ngokupheleleyo kwaye ungayityumzi, uyihlafune, okanye uyaphule. Unokuthatha iBelviq kunye okanye ngaphandle kokutya. Kuya kufuneka ulahle ubuncinci i-5% yesisindo sakho sokuqala kwiiveki ezili-12 zokuqala ukuthatha iBelviq kunye nokutya ukutya okuncinci kweekhalori.

Ungaphantsi kobunzima obungakanani ngebelviq?

I-Lorcaserin, esetyenziswa ngokudibanisa nokutya kunye nokuzilolonga, ikhokelela ekunciphiseni ubunzima obumalunga ne-12.9 lb (5.8 kg) xa kuthelekiswa ne-5.6 lb (2.5 kg) kunye ne-placebo.

Uza kuthatha ixesha elingakanani belviq?

Unokuthatha iBelviq kunye okanye ngaphandle kokutya. Kuya kufuneka ulahle ubuncinci i-5% yesisindo sakho sokuqala kwiiveki ezili-12 zokuqala ukuthatha iBelviq kunye nokutya ukutya okuncinci kweekhalori. Biza ugqirha wakho ukuba awulahleki ubuncinci i-5% yesisindo sakho sokuqala emva kokuthatha iyeza iiveki ezili-12.

Uziva njani u-belviq?

I-Belviq yaziwa ngokuba yi-serotonin 2C receptor agonist, oko kuthetha ukuba iyenza isebenze iindawo ezithile zobuchopho ezikwenza uzive ugcwele. Indlala encinci ikhokelela ekutyeni okuncinci, okukhokelela ekunciphiseni ubunzima.

Zithini iziphumo zelorcaserin?

Iziphumo ebezingalindelekanga zeBelviq zibandakanya: iswekile esezantsi yegazi (hypoglycemia), iingxaki zengqondo, ukubetha kwentliziyo kancinci, intloko ebuhlungu, isiyezi, ukozela, ukudinwa, ukudinwa,

Ngaba ungasela utywala ngelixa uthatha i-belviq?

Ngaba onke amanqanaba okunciphisa umzimba ayadibana notywala? Ayizizo zonke iziyobisi ezilahlekileyo ezinobunzima ezinxibelelana neziyobisi notywala; Umzekelo, i-lorcaserin (i-Belviq, i-Belviq XR) kunye ne-orlistat (i-Alli, i-Xenical) ayidwelisi ukusebenzisana kweziyobisi kwilebheli yemveliso.

Ngaba i-belviq ingabangela ukuzuza kwesisindo?

Iziphumo ezincinci. Abantu abathatha iyeza lonyaka banokulindela ukuphulukana ne-3 ukuya kwi-3.7 yepesenti yobunzima babo, kwaye banokufumana ubunzima kwakhona, uphando lubonisa. Kwilingo elinye, abaguli abathatha iBelviq baphulukana neepesenti ezi-5 zomzimba wabo emva kweenyanga ezili-12, kodwa bafumana ama-25 eepesenti ekupheleni konyaka wesibini.

Kukuphi okungcono ukuphikisana okanye ibelviq?

UBelviq kunye noContrave bakwiiklasi ezahlukeneyo zeziyobisi. I-Belviq yi-serotonin 2C receptor agonist kunye ne-Contrave yindibaniselwano ye-opioid antagonist kunye ne-antidepressant.

Ngaba i-belviq iyasebenza ngokwenene?

Abantu abathatha iyeza lonyaka banokulindela ukuphulukana ne-3 ukuya kwi-3.7 yepesenti yobunzima babo

Ngaba i-belviq iyafana nePhentermine?

I-Belviq (i-lorcaserin hydrochloride) kunye ne-Adipex-P (phentermine) zisetyenziselwa ukulawulwa kobunzima kwizigulana ezityebileyo ukongeza ekutyeni nasekuzilolongeni. IBelviq isetyenziselwa ulawulo lobunzima obungapheliyo.

Ngaba ibelviq iyanqanyulwa?

Ulawulo lwe-US Food and Drug Administration (i-FDA) lucele ukuba umenzi weBelviq, uBelviq XR (lorcaserin) ngokuzithandela arhoxe iziyobisi ezilahlekayo ubunzima kwimakethi yaseMelika.

Ucaphulo

  1. UTaylor, J., uDetretr, uE, kunye noPowell, J. (2013). I-Lorcaserin yoLawulo loBunzima. Iswekile, iMetabolic Syndrome, kunye nokuTyeba kakhulu.
  2. IHoy, SM (2013). I-Lorcaserin: Uphengululo loSetyenziso lwayo kuLawulo lweSisindo esingapheliyo. Iziyobisi.
  3. IHess, R., kunye noMnqamlezo, i-LB (2013). Ukhuseleko kunye nokusebenza kweLorcaserin kuLawulo lokuTyeba kakhulu. Unyango lwasemva kwesidanga.
  4. UBrashier, DB, Sharma, AK, Dahiya, N., kunye no-Singh, SK (2014). I-Lorcaserin: Inoveli yokulwa nesiyobisi. Ijenali yeFarmacology kunye neFarmacotherapeutics.
  5. UChan, EW okqhubekayo. (2013). Ukusebenza kunye noKhuseleko lweLorcaserin kubantu abadala abatyebileyo: Uhlalutyo lweMeta yoNyaka o-1 woLingo oluLungelelanisiweyo (RCTs) kunye noPhononongo lokuBalisa kwiiRCTs zeXesha elifutshane. Ukutyeba kakhulu.
  6. INigro, SC, Luon, D., kunye no-Baker, WL (2013). I-Lorcaserin: Inoveli yeSerotonin 2C Agonist yoNyango lokuTyeba kakhulu. Uphando lwangoku lwezoNyango kunye neMbono.